乌地那非(Udenafil) - 药物靶点：PDE5A_在研适应症：勃起功能障碍，单心室心脏_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Udenafil (USAN/INN)、Udzire、Zydena

+ [7]

靶点

PDE5A

作用方式

抑制剂

作用机制

PDE5A抑制剂(磷酸二酯酶-5A抑制剂)

治疗领域

泌尿生殖系统疾病心血管疾病遗传病与畸形+ [1]

在研适应症

勃起功能障碍单心室心脏

非在研适应症

阿尔茨海默症慢性收缩性心力衰竭认知功能障碍+ [13]

原研机构

Dong-A Pharmaceutical Co., Ltd. (Old)

在研机构

Dong-A ST Co., Ltd.

Mezzion Pharma Co., Ltd.

Dong-A Pharmaceutical Co., Ltd. (Old)

非在研机构

Dr. Falk Pharma GmbH

Meiji Seika Pharma Co., Ltd.

权益机构

Mezzion Pharma Co., Ltd.

Tabuk Pharmaceuticals Manufacturing Co.

最高研发阶段批准上市

首次获批日期

韩国 (2005-11-29),

勃起功能障碍

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C25H36N6O4S

InChIKeyIYFNEFQTYQPVOC-UHFFFAOYSA-N

CAS号268203-93-6

关联

44

项与乌地那非相关的临床试验

NCT05918211

/ Recruiting临床3期

Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL-2)

This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.

开始日期2023-10-30

申办/合作机构

Mezzion Pharma Co., Ltd.

KCT0005833

/ Completed临床4期IIT

Effect of Udenafil Administration for Blood Flow Increase in the Prefrontal Cortex

开始日期2020-12-01

申办/合作机构-

NCT03430583

/ Completed临床3期

Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study

A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.

开始日期2018-02-20

申办/合作机构

Mezzion Pharma Co., Ltd.

[+1]

100 项与乌地那非相关的临床结果

登录后查看更多信息

100 项与乌地那非相关的转化医学

登录后查看更多信息

100 项与乌地那非相关的专利（医药）

登录后查看更多信息

224

项与乌地那非相关的文献（医药）

2026-09-22·ONCOGENE

Transcription factor EN1 governs a lipogenic USP18-ACLY axis to drive bladder cancer malignancy

Article

作者: Yin, Zhuo ; Li, Xiangya ; Zhan, Ying ; Zhu, Chenxi ; Wen, Chuqi ; Guo, Xiaoyan ; Li, Yang ; Hu, Jia

Bladder cancer (BLCA) is a lethal malignancy with limited therapeutic options. The role of the transcription factor Engrailed-1 (EN1) in BLCA metabolic reprogramming was previously unknown. Our study demonstrates that EN1 is significantly overexpressed in BLCA, correlating with poor patient survival and driving tumor progression. Mechanistically, EN1 transcriptionally upregulates the deubiquitinase USP18. USP18, in turn, prevents the proteasomal degradation of ATP-citrate lyase (ACLY), thereby stabilizing this gatekeeping enzyme to enhance de novo lipogenesis. Crucially, we identified the FDA-approved drug Udenafil as a candidate EN1-targeting compound. Udenafil suppressed the USP18/ACLY axis and inhibited BLCA progression in preclinical models. This study defines the EN1-USP18-ACLY axis as a master regulator of lipogenesis and a promising therapeutic target in BLCA, supporting the repositioning of Udenafil as a potential treatment strategy.

2026-07-01·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

An integrative machine learning and structure-driven drug repositioning strategy for human IRAK4-targeted cancer therapy

Article

作者: Shen, Xiaolin ; Raza, Muhammad Ali ; Ahmad, Muneer ; Iqbal, Muhammad Waleed ; Sun, Xinxiao ; Lv, Jianlong

The upregulation of interleukin-1 receptor-associated kinase 4 (IRAK4) drives pro-tumorigenic signaling across various malignancies. Currently available IRAK4 inhibitors are all limited by suboptimal selectivity and off-target toxicity. To develop non-toxic and mechanistically focused IRAK4 inhibitors, an in silico machine learning (ML) pipeline combined with structure-driven drug repositioning was employed. An IRAK4-targeting dataset of bioactive compounds was systematically filtered and curated to train a random forest (RF) regression model. Comparative cross-validation against 41 independent ML frameworks demonstrated reasonable predictive accuracy, and the optimized model was deployed to screen a library of 1040 FDA-approved therapeutics. Orthogonal molecular docking supported the binding efficacy of RF-identified lead compounds, including udenafil, linagliptin, benflumetol, and nimodipine. Thermodynamic and conformational stability were validated using molecular dynamics (MD) simulations, yielding stable root mean square deviation (RMSD), radius of gyration (R_g), root mean square fluctuation (RMSF), principal component analysis (PCA), hydrogen bonding, and MMGBSA/MM-PBSA profiles. The efficacy of these candidates was further supported by their low toxicity profiles, via graph neural network (GNN)-based toxicity analysis. These findings establish a scalable computational strategy for identifying repurposable oncology therapeutics and propose udenafil, linagliptin, benflumetol, and nimodipine as mechanistically credible candidates for experimental validation.

2025-08-19·Journal of the American Heart Association

Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL Trial

Article

作者: Orr, William B. ; Goldberg, David J. ; Nowlen, Todd T. ; Ploutz, Michelle ; Frischhertz, Benjamin P. ; DiMaria, Michael V. ; McCrindle, Brian W. ; Lubert, Adam M. ; Cartoski, Mark J. ; Goldstein, Bryan H. ; McHugh, Kimberly E. ; Penny, Daniel J. ; Garg, Ruchira ; Zak, Victor ; Ginde, Salil ; Schumacher, Kurt R. ; Yauck, Jennifer S. ; Whitehill, Robert ; Mackie, Andrew S. ; Davis, Christopher K. ; Yetman, Anji T. ; Rathod, Rahul H. ; Wagner, Jonathan B. ; Kim, Gi Beom ; Payne, R. Mark ; Paridon, Stephen M. ; Pearson, Gail D. ; McBride, Michael G. ; Yeager, James ; Hill, Kevin D. ; Hu, Chenwei ; Richmond, Marc E. ; Detterich, Jon ; John, Anitha S. ; Files, Matthew

Background:

In the FUEL (Fontan Udenafil Exercise Longitudinal) trial, a positive treatment effect was identified for outcomes at the ventilatory anaerobic threshold but not for the primary outcome, oxygen consumption (V o2 ) at peak exercise. This disparate response may be explained by the physiologic challenge of improving peak V o2 in participants with near‐normal baseline exercise performance.

Methods:

Participants were divided into subgroups by baseline predicted peak V o2 (<80% versus ≥80%). Treatment effect was evaluated in those with a baseline peak V o2 <80% predicted and linear regression was performed to examine the interaction between subgroup and response to therapy for the primary and secondary outcomes.

Results:

Of the 379 participants with paired exercise data, 302 (80%) had a baseline peak V o2 <80% predicted. In this subgroup, the primary outcome of peak V o2 improved significantly after 6 months of udenafil treatment, when compared with placebo (0.23±4.17 mL/kg per min versus −0.90±3.74 mL/kg per min; P =0.021). Secondary outcome measures, including V o2 at ventilatory anaerobic threshold ( P =0.023), work at ventilatory anaerobic threshold ( P =0.032), and the myocardial performance index ( P =0.007) were all significantly improved as well. A significant interaction was found between exercise subgroups and response to udenafil for peak V o2 ( P =0.036) but not for other outcomes.

Conclusions:

In this post hoc subgroup analysis, after exclusion of patients with Fontan circulation with near‐normal baseline peak V o2 , a positive treatment effect of udenafil was identified for the primary outcome of peak V o2 . The interaction between baseline peak V o2 and treatment may have influenced the outcome of the FUEL trial.

Registration:

URL: https://clinicaltrials.gov ; Unique identifier: NCT0274115.

28

项与乌地那非相关的新闻（医药）

2026-08-02

·PRNewswire

Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD

Seoul, Korea, Aug. 2, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. today announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD). In a preclinical ADPKD model, udenafil reduced kidney cyst burden and blood urea nitrogen (BUN), a blood marker linked to kidney function, compared with controls. Both findings were statistically significant and consistent across the treatment groups evaluated. The study also showed evidence of activity on udenafil's intended cyclic guanosine monophosphate (cGMP) signaling pathway in the kidney. In addition, udenafil produced a statistically significant reduction in a preclinical measure of cardiac hypertrophy, or heart enlargement. Because cardiovascular complications are an important part of ADPKD, this finding supports further study of udenafil's potential effects on cardiac remodeling. The study was conducted at Mayo Clinic in Florida, with Fouad T. Chebib, M.D., serving as principal investigator. The results build on two earlier preclinical studies in which udenafil inhibited cyst growth and reduced cyst burden. Across these complementary ADPKD models, udenafil has shown activity on its intended cGMP pathway, reduced measures of cystic disease, and improved a biochemical measure used in kidney assessment. Together, the data support clinical evaluation in people with ADPKD. "These findings strengthen the scientific rationale for advancing udenafil in ADPKD," said Dong Hyun Park, Chairman and CEO of Mezzion. "As previously announced, the U.S. Food and Drug Administration (FDA) indicated that Mezzion's nonclinical data package, together with its prior clinical and safety experience with udenafil, provides a reasonable foundation for clinical development. Udenafil has been studied in multiple clinical programs over approximately 20 years, including studies with multi-year exposure. This experience will help inform ADPKD study design and safety monitoring." "The consistency across multiple preclinical models is encouraging and supports evaluating udenafil in a well-designed Phase 2b study using established measures of ADPKD progression," said Ronald D. Perrone, M.D., of Tufts Medicine. "Patients with ADPKD need more treatment options for this serious, lifelong disease," said Ridwan Shabsigh, M.D., FACS, President and COO of Mezzion. "Advancing udenafil in ADPKD gives Mezzion a second rare-disease development program alongside our ongoing Phase 3 FUEL-2 study." "The preclinical data provide a compelling scientific rationale for clinical evaluation in ADPKD. Unlike vasopressin V2 receptor antagonists, udenafil is being investigated through modulation of the nitric oxide-cGMP pathway, providing a mechanistically distinct therapeutic approach. We look forward to participating in the study," said Professor Yong Chul Kim of Seoul National University Hospital. ADPKD is a progressive genetic kidney disease affecting approximately 1 in 400 to 1,000 people worldwide. As kidney cysts grow, kidney function can decline and ultimately lead to dialysis or kidney transplantation. ADPKD is also associated with cardiovascular and other complications. Mezzion plans to advance udenafil into a Phase 2b study in adults at risk of rapidly progressing ADPKD, subject to finalization of the protocol and receipt of regulatory and ethics approvals. The planned study is expected to evaluate kidney volume and function, disease-related biomarkers, pharmacokinetics, safety, and tolerability. About Mezzion Pharma Co., Ltd. Mezzion Pharma Co., Ltd., based in Korea and listed on the KOSDAQ (140410), is a clinical-stage biopharmaceutical company focused on developing therapies for rare and underserved diseases. The Company is developing udenafil across multiple potential indications, including Fontan circulation and ADPKD. Udenafil is an investigational product and has not been approved by any regulatory authority. Media Contacts: John Presser, EVP, CBO: [email protected] Mr. Sung-Il Noh, CFO: [email protected] SOURCE Mezzion Pharma Co., Ltd. 21% more press release views with Request a Demo

临床结果临床2期

2026-07-16

·PRNewswire

FUEL FALD Study Published in Pediatric Cardiology

Peer-reviewed publication advances understanding of Fontan-associated liver disease (FALD) and adds to the growing body of evidence supporting udenafil in Fontan circulation FORT LEE, N.J., July 16, 2026 /PRNewswire/ -- Mezzion Pharmaceuticals today announced publication of "The FUEL FALD Study: Effects of Udenafil on Liver Stiffness and Fibrosis after Fontan" in the peer-reviewed journal Pediatric Cardiology. The publication reports findings from an exploratory substudy of the FUEL Open Label Extension (OLE) evaluating Fontan-associated liver disease (FALD) in adolescents and young adults who received 12 months of udenafil treatment. As survival following the Fontan procedure has improved, FALD has emerged as one of the most important long-term complications affecting patients living with Fontan circulation. Driven by the unique Fontan physiology, FALD is characterized by progressive liver injury and fibrosis and remains an area of significant unmet medical need, with no approved therapies specifically indicated for this condition. The publication highlights the substantial burden of liver disease in this population. At study entry, 95% of participants had elevated Enhanced Liver Fibrosis (ELF) scores, consistent with at least moderate fibrosis based on thresholds established in other liver diseases. Liver stiffness was also assessed using ultrasound shear wave elastography (SWE) and magnetic resonance elastography (MRE) . Following 12 months of udenafil treatment, investigators observed a significant decrease in the ELF score, a non-invasive biomarker associated with fibrotic remodeling, with 84% of participants demonstrating a reduction over the study period. Although liver stiffness measurements did not significantly change, the authors concluded that the findings suggest the possibility that udenafil may alter the overall Fontan fibrotic milieu and warrant further study. The publication adds to a growing body of peer-reviewed evidence from the FUEL clinical program examining udenafil across multiple dimensions of Fontan physiology, including exercise capacity, ventricular performance, cardiovascular safety, nitric oxide pathway biology, patient experience, and liver fibrosis biomarkers. "As patients with Fontan circulation continue to live longer, understanding and addressing the long-term complications of Fontan physiology has become increasingly important," said Kurt Schumacher, M.D., Chief of Pediatric Cardiology at University of Michigan Health C.S. Mott Children's Hospital and lead author of the publication. "These findings contribute to our growing understanding of Fontan-associated liver disease and reinforce the importance of continuing to investigate therapies that may address this serious long-term complication." "Fontan-associated liver disease is one of the most serious long-term complications of Fontan circulation, and patients and clinicians have very limited options to address it." said Ridwan Shabsigh, M.D., F.A.C.S, President and COO of Mezzion, "The FUEL FALD Study provides important new insight into the potential role of udenafil in the fibrotic process associated with Fontan physiology and supports continued investigation of this complex disease." "The breadth of research emerging from the FUEL program is providing increasingly comprehensive view of Fontan physiology and the potential role of udenafil," said Dean Park, Chairman and CEO of Mezzion. " As we advance through the final phase of enrollment in the confirmatory Phase 3 FUEL-2 trial, we remain focused on developing the first therapy specifically indicated for patients living with Fontan circulation." Mezzion gratefully acknowledges the patients and families who participated in the FUEL clinical program, the investigators and participating clinical sites, and the Pediatric Heart Network for their contributions to advancing research in Fontan circulation. About the FUEL-2 Trial FUEL-2 is Mezzion's global confirmatory Phase 3 trial evaluating udenafil in adolescents and young adults with Fontan circulation. The study is designed to evaluate exercise capacity and support potential regulatory approval of udenafil as the first therapy specifically developed for patients living with Fontan circulation. Learn more at . Publication The full publication is available in Pediatric Cardiology: About Mezzion Pharmaceuticals Mezzion Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare cardiovascular and renal diseases. Its lead investigational product, udenafil, is being evaluated in the global Phase 3 FUEL-2 trial for single ventricle congenital heart disease patients living with Fontan circulation. Mezzion Pharmaceuticals is the U.S. subsidiary of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410). Learn more at . Forward-Looking Statements This press release contains forward-looking statements regarding the future development of Mezzion's investigational product candidates, including statements relating to the clinical development of udenafil, the FUEL-2 trial, regulatory interactions, potential regulatory approvals, future research, and anticipated clinical outcomes. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Mezzion undertakes no obligation to update any forward-looking statements except as required by applicable law. Media & Investor Contacts John Presser Executive Vice President & Chief Business Officer [email protected] Sung-Il Noh Chief Financial Officer [email protected] SOURCE Mezzion Pharmaceuticals, Inc 21% more press release views with Request a Demo

临床3期临床结果

2026-06-05

·PRNewswire

Mezzion Pharma Completes FUEL-2 Phase 3 Regulatory Milestone

After independent review, study continues as planned with enrollment on track for completion in 2026 SEOUL, South Korea and FORT LEE, N.J., June 5, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. (KOSDAQ: 140410) today announced the results of a planned independent, blinded statistical review of its ongoing global confirmatory Phase 3 FUEL-2 study evaluating udenafil, its investigational therapy for single ventricle heart disease with Fontan circulation. After 50% of the planned study population completed the study's 26-week treatment period, an independent assessment was conducted to determine whether an increase in sample size would be required to maintain the study's planned statistical assumptions. The independent review determined that no increase in sample size was required and recommended that the study continue as planned with the enrollment of 436 patients. Moreover, no changes were recommended to the study design, primary endpoint, statistical analysis plan, or projected study timelines. "We believe the successful completion of this independent review marks an important milestone for the FUEL-2 program," said Dean Park, Chairman and CEO of Mezzion Pharma. "We remain focused on advancing udenafil toward becoming the first approved therapy specifically indicated for patients with single ventricle heart disease with Fontan circulation." Mezzion Pharma has now completed all major planned statistical review milestones prior to topline data. Single ventricle heart disease with Fontan circulation is a rare and serious form of congenital heart disease associated with significant long-term complications. Despite advances in surgical care, there are currently no approved therapies specifically indicated for this rare disease with unmet medical need. About Mezzion Pharma Mezzion Pharma Co., Ltd. (KOSDAQ: 140410) is a late-stage biopharmaceutical company focused on developing therapies for rare cardiovascular and renal diseases. Its lead program, udenafil, is being developed as a potential first therapy specifically indicated for patients with Fontan circulation. Udenafil is an investigational product and has not been approved by any regulatory authority. Mezzion conducts its U.S. operations through its wholly owned subsidiary, Mezzion Pharmaceuticals, Inc. For more information, visit mezzion.com or FUEL2Study.com. Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of Mezzion Pharma, including statements regarding clinical development timelines, regulatory activities, potential approval of udenafil, and anticipated study outcomes. Actual results may differ materially from those expressed or implied by these forward-looking statements. Mezzion undertakes no obligation to update any forward-looking statements except as required by applicable law. Media Contacts: John Presser, EVP, CBO: [email protected] Mr. Sung-Il Noh, CFO: [email protected] SOURCE Mezzion Pharma Co., Ltd. 21% more press release views with Request a Demo

临床3期

100 项与乌地那非相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10027	乌地那非	G04BE11	DB06267

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
勃起功能障碍	韩国	Dong-A Pharmaceutical Co., Ltd. (Old)	2005-11-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
单心室心脏	临床3期	美国	Mezzion Pharma Co., Ltd.	2016-07-22
单心室心脏	临床3期	加拿大	Mezzion Pharma Co., Ltd.	2016-07-22
单心室心脏	临床3期	韩国	Mezzion Pharma Co., Ltd.	2016-07-22
肺动脉高压	临床3期	韩国	Dong-A ST Co., Ltd.	2014-04-01
阿尔茨海默症	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd. (Old)	2013-09-01
射血分数保留型心力衰竭	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd. (Old)	2012-10-01
舒张期心力衰竭	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd. (Old)	2012-10-01
特发性肺动脉高压	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd. (Old)	2012-09-01
门静脉高血压	临床3期	奥地利	Dr. Falk Pharma GmbH	2012-04-04
肝硬化	临床3期	奥地利	Dr. Falk Pharma GmbH	2012-04-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03013751 (FUELExten, CTgov)	临床3期	单心室心脏	301	Udenafil (In PHN-Udenafil-02 (FUEL) Received Udenafil)	鏇鹹選窪醖鬱窪鑰顧窪(憲膚顧製餘憲糧膚淵膚) = 窪積觸鹽鏇積夢遞簾製鏇壓齋繭繭顧糧觸襯鏇 (觸選衊淵範獵廠廠憲鹽, 470.80) 更多	-	2025-12-09
				Udenafil (In PHN-Udenafil-02 (FUEL) Received Placebo)	鏇鹹選窪醖鬱窪鑰顧窪(憲膚顧製餘憲糧膚淵膚) = 夢廠夢構構夢壓鹹膚淵鏇壓齋繭繭顧糧觸襯鏇 (觸選衊淵範獵廠廠憲鹽, 444.26) 更多
NCT03430583 (FALD, CTgov)	临床3期	单心室心脏	88	Udenafil (Udenafil Continuation (U+))	艱壓獵繭遞繭遞製齋選(繭獵鏇獵鏇艱選蓋獵艱) = 艱簾淵壓廠觸鹹餘選糧艱艱衊鹹艱鹹窪蓋遞鏇 (醖願廠選選膚膚鹹醖壓, 0.380) 更多	-	2025-09-18
				Udenafil (Udenafil Naive (U-))	艱壓獵繭遞繭遞製齋選(繭獵鏇獵鏇艱選蓋獵艱) = 憲顧壓鬱膚醖餘壓窪顧艱艱衊鹹艱鹹窪蓋遞鏇 (醖願廠選選膚膚鹹醖壓, 0.450) 更多
NCT02741115 (FUEL, CTgov)	临床3期	单心室心脏	400	Placebo (Placebo)	鹹憲醖壓憲夢獵艱繭廠(鏇簾夢窪範遞衊衊膚簾) = 衊築壓鬱鏇範願鹹製鏇鬱艱築構鬱鏇夢餘選範 (醖壓襯鑰願繭鬱齋構鹽, 3.672) 更多	-	2025-05-21
				Udenafil (Drug)	淵窪壓鬱廠網遞窪糧顧(願構餘餘願製鬱壓獵築) = 襯構糧鬱範觸選齋鹹憲衊憲網廠鏇範鹽選艱顧 (獵醖窪壓選網願築構製, 0.112) 更多
NCT01553721 (Pubmed \| Clin Ther)	临床2期	肺动脉高压	63	Udenafil 50-mg	醖夢願憲壓繭觸築網醖(膚構製鹽構蓋衊範憲鹹) = 選鑰醖製窪構夢廠築襯糧獵鑰遞願顧襯願壓壓 (遞襯壓膚製願製鬱構鏇 )	积极	2019-08-01
NCT01553721 (Pubmed \| Korean Circ J)	临床2期	肺动脉高压	63	Udenafil 50 mg	積壓遞構醖醖糧齋製鏇(選憲夢夢齋鬱積製糧範) = 築襯簾觸鏇構壓襯膚鑰憲顧構鏇憲製鹹顧選鑰 (遞淵願範鑰鹹廠鬱夢憲 ) 更多	-	2019-04-01
				Udenafil 100 mg	積壓遞構醖醖糧齋製鏇(選憲夢夢齋鬱積製糧範) = 蓋鹽窪壓遞齋壓膚鑰壓憲顧構鏇憲製鹹顧選鑰 (遞淵願範鑰鹹廠鬱夢憲 ) 更多
KCT0001436 (Pubmed \| J Clin Pharmacol)	临床1期	-	-	Udenafil (Healthy young men (21-27 years))	遞願蓋鏇廠衊鑰廠範襯(鬱遞鏇廠範鑰醖觸鹹醖) = 淵繭製顧夢鏇構願憲範鹽夢鬱網餘膚鬱願鏇獵 (膚艱選範願淵觸糧糧築 ) 更多	-	2016-11-01
				Udenafil (Healthy elderly men (65-78 years))	遞願蓋鏇廠衊鑰廠範襯(鬱遞鏇廠範鑰醖觸鹹醖) = 簾窪壓窪齋築鏇餘獵鏇鹽夢鬱網餘膚鬱願鏇獵 (膚艱選範願淵觸糧糧築 ) 更多
NCT01280266 (EULAR2014)	临床2/3期	雷诺病	12	Udenafil 100 mg/day	遞夢餘網範顧築鬱糧襯(醖觸鑰醖鑰積願鑰繭餘) = 鹹醖鹽窪鹽鏇醖網選壓鹹鏇糧齋鬱築憲鬱蓋鏇 (蓋構顧積選淵鹹夢繭鏇 ) 更多	-	2014-06-11
NCT01280266 (CTgov)	临床2/3期	雷诺病	29	Amlodipine (Amlodipine)	齋醖壓遞夢壓鏇獵憲遞(襯膚構構願蓋淵獵遞糧) = 遞鏇淵願選製齋餘願淵獵鑰遞簾鬱憲獵襯鹹鏇 (範觸淵膚鏇簾醖齋醖艱, 1.4) 更多	-	2012-12-11
				Udenafil (Udenafil)	齋醖壓遞夢壓鏇獵憲遞(襯膚構構願蓋淵獵遞糧) = 築壓壓鏇憲窪壓糧築願獵鑰遞簾鬱憲獵襯鹹鏇 (範觸淵膚鏇簾醖齋醖艱, 0.9) 更多
NCT01364181 (Pubmed \| COPD)	临床3期	慢性阻塞性肺疾病	23	Udenafil 50 mg	鹹壓齋醖築艱衊鑰簾鹹(窪遞鬱願衊構選網膚遞) = 餘淵餘衊鏇鏇淵範選願淵簾築艱願獵鏇繭艱憲 (壓鹽醖淵壓鬱艱夢願膚 ) 更多	-	2012-08-01
NCT01037244 (CTgov)	临床3期	勃起功能障碍	618	Udenafil (Udenafil 50 mg)	積醖艱顧蓋衊鑰簾選範(廠醖壓積襯鬱鬱鹹衊製) = 遞齋膚繭鑰醖淵餘簾壓觸獵遞憲鬱膚艱餘醖選 (壓夢顧繭鑰艱積艱壓網, 蓋網鑰蓋艱艱鏇獵鹽夢 ~ 簾窪網鑰願餘糧襯選選) 更多	-	2011-12-22
				Udenafil (Udenafil 100 mg)	積醖艱顧蓋衊鑰簾選範(廠醖壓積襯鬱鬱鹹衊製) = 窪觸製廠襯憲鬱觸願蓋觸獵遞憲鬱膚艱餘醖選 (壓夢顧繭鑰艱積艱壓網, 艱衊鑰製壓憲淵衊鬱鬱 ~ 壓夢淵遞積網襯觸淵窪) 更多